NRD
MDGL icon

Nebula Research & Development’s Madrigal Pharmaceuticals MDGL Stock Holding History

Nebula Research & Development’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,552
Closed -$957K – 787
2023
Q3 		$957K Buy
6,552
+4,082
+165% +$768K 0.5% 20
2023
Q2 		$571K Buy
2,470
+1,335
+118% +$362K 0.43% 109
2023
Q1 		$275K Buy
+1,135
New +$309K 0.49% 125

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nebula Research & Development's MDGL Position: Q4 2023 in Review

Nebula Research & Development sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 6,552 shares — an estimated $957K sold.

Nebula Research & Development first reported a position in MDGL in Q1 2023 and held it in 3 quarters. The position peaked at $957K in Q3 2023. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

  • Nebula Research & Development reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Nebula Research & Development sold 6,552 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $957K.
  • Nebula Research & Development first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Nebula Research & Development's Madrigal Pharmaceuticals position peaked at $957K in Q3 2023.
  • 226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on Nebula Research & Development's 13F filing for Q4 2023, filed 14 Feb 2024.